ClinicalTrials.gg
RecruitingNCT06533761Updated Oct 20, 2026

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS

A Phase 1 interventional study of Eganelisib and Eganelisib in combination with cytarabine in AML, Adult and MDS, sponsored by Stelexis BioSciences. Recruiting at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Stelexis BioSciences · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.
Updated Oct 20, 2026Site recruiting status changedPrimary completion moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 247 studies testing cytarabine in Leukemia, Myeloid, Acute — 39 open to participants now, 45 under way, 10 of them phase 3. Cytarabine · Leukemia, Myeloid, Acute.

Planned enrollment
58th of 239
105 · median 48
Started
2025
with 7 others
Phase 1
54 of 247
4 open now
Primary completion
2027-12
later than 19 of 44 live
Registered
229th of 247
by date

Among the 247 studies testing cytarabine in Leukemia, Myeloid, Acute, this one is the 58th largest by planned enrollment of the 239 interventional ones that give a count, is one of 8 that started in 2025, is one of 54 in phase 1, reaches primary completion later than 19 of the 44 other live ones, and was the 229th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

39 of the 247 studies testing cytarabine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

33 more — sign in →

By country, each count listing its studies:

All 39 open studies →

About cytarabine

Cytarabine: first FDA approval 1969 (CYTARABINE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 247 studies testing cytarabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This is a Phase 1b open-label, multicenter, dose-escalation and randomized combination cohort study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor efficacy of eganelisib as monotherapy and in combination with cytarabine in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) or r/r higher-risk myelodysplastic syndromes (HR-MDS) and in combination with azacitidine in PI3K-Gamma-Positive patients with previously untreated HR-MDS.

The study consists of 2 parts:

  • Part 1: Dose Escalation (DE) in both monotherapy and in combination with cytarabine.
  • Part 2: Randomized Combination Cohort: eganelisib + azacitidine and azacitidine alone
03

Conditions studied

  • AML, Adult
  • MDS
04

Who can participate

The criteria were revised on the registry on Oct 20, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Part 1: Pathological diagnosis of either: AML according to World Health Organization (WHO) 2022 revised criteria per the local pathology report and with ≥10% bone marrow blasts (acute promyelocytic leukemia is excluded but secondary AML and treatment-related AML can be included); Higher-risk (IPSS-R Intermediate, High or Very High Risk at time of study entry) myelodysplastic syndromes (HR-MDS) according to WHO 2022 revised criteria per the local pathology report and with ≥10% bone marrow blasts.
  • Part 2: Pathological diagnosis of previously untreated HR-MDS according to WHO 2022 revised criteria, with bone marrow blasts ≥5% and \<20%; Moderate or higher PI3K-Gamma in bone marrow blasts, as determined by an IHC assay; Deemed by the Investigator to require frontline therapy with azacitidine.
  • (ECOG) performance status ≤2.
  • Adequate hepatic and renal function measured within 7 days prior to the first dose of eganelisib.

Exclusion criteria

Exclusion Criteria:

  • or allogeneic stem cell transplant within 6 months prior to Cycle 1 Day 1.
  • Receiving (eg, cyclosporin) or systemic (except for steroid use as cortisol replacement therapy in documented adrenal insufficiency).
  • Active fungal disease or uncontrolled infection of any kind; patients receiving antibiotic, antifungal or antiviral treatment must be afebrile and hemodynamically stable for >72 hours prior to treatment
  • WBC count >25 × 10\^9/L measured within 7 days prior to the first dose of eganelisib (hydroxyurea is permitted to decrease the WBC count).
  • Presence of a non-hematologic toxicity of prior therapy that has not resolved to Grade ≤1 or Baseline, whichever is worst, as determined by v 5.0, except alopecia or skin pigmentation. Fatigue and neuropathy must have resolved to Grade ≤2.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    Eganelisib

    Drug: Eganelisib

  • Experimental
    Eganelisib in combination with cytarabine

    Drug: Eganelisib in combination with cytarabine

  • Experimental
    Eganelisib in combination with azacitidine

    Drug: Eganelisib in combination with azacitidine

  • Active comparator
    Azacitidine

    Drug: Azacitadine (AZA)

Interventions

  • eganelisib will be administered as monotherapy

  • DrugEganelisib in combination with cytarabine

    Drug pages: IPI-549 · Cytarabine

    eganelisib will be administered in combination with cytarabine

  • DrugEganelisib in combination with azacitidine

    Drug pages: IPI-549 · Azacitidine

    eganelisib will be administered in combination with azacitidine

  • azacitidine will be administered as standard of care

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0

    Time frame: 12 months

  2. Incidence and severity of dose-limiting toxicities (DLTs) in DLT evaluable patients during Cycle 1

    Time frame: 28-35 days

Secondary outcomes

  1. Preliminary clinical activity as evaluated per European LeukemiaNet (ELN) 2022 criteria for AML and International Working Group (IWG) 2023 criteria for HR-MDS and FDA 2025 draft guidance

    Time frame: 12 months

  2. Area under the plasma concentration time curve extrapolated to the last measurable time point [AUClast] of eganelisib, cytarabine, and azacitidine

    Time frame: 112 days

  3. Maximum concentration [Cmax] of eganelisib, cytarabine, and azacitidine

    Time frame: 112 days

  4. Time of maximum concentration [Tmax] of eganelisib, cytarabine, and azacitidine

    Time frame: 112 days

  5. Plasma half-life [t1/2] of eganelisib, cytarabine, and azacitidine

    Time frame: 112 days

  6. Measure plasma concentrations of eganelisib and determine model-based PK parameters

    Time frame: 112 days

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2027, 31 months after the start.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's planned 31 months is below that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jul 2027 → Dec 2027 and completion Mar 2028 → Sep 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2024
First posted
Aug 1, 2024
StartActual
Apr 28, 2025
Primary completionEst.
Dec 15, 2027was Jul 2027
CompletionEst.
Sep 15, 2028was Mar 2028
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed. Memorial Sloan Kettering Cancer Center is now Recruiting
Show 1 removed
  • Memorial Sloan Kettering Cancer Center · New York, United States
Oct 20, 2026
Primary completion
Jul 15, 2027→Dec 15, 2027
Oct 20, 2026
Study completion
Mar 15, 2028→Sep 15, 2028
Oct 20, 2026
Enrollment
125→105
Oct 20, 2026
Eligibility
1 inclusion criterion edited, 1 added
What changed in the criteria
Inclusion criteria
  • EditedPart 1: Pathological diagnosis of either: AML according to World Health Organization (WHO) 2022 revised criteria per the local pathology report and with ≥10% bone marrow blasts (acute promyelocytic leukemia is excluded but secondary AML and treatment-related AML can be included); Higher-risk (IPSS-R Intermediate, High or Very High Risk at time of study entry) myelodysplastic syndromes (HR-MDS) according to WHO 2022 revised criteria per the local pathology report and with ≥10% bone marrow blasts.
  • AddedPart 2: Pathological diagnosis of previously untreated HR-MDS according to WHO 2022 revised criteria, with bone marrow blasts ≥5% and <20%; Moderate or higher PI3K-Gamma in bone marrow blasts, as determined by an IHC assay; Deemed by the Investigator to require frontline therapy with azacitidine.
Oct 20, 2026
Interventions
Added Drug: Eganelisib in combination with azacitidine·Drug: Azacitadine (AZA). Arms added: Eganelisib in combination with azacitidine·Azacitidine
Oct 20, 2026
Primary outcomes
1 removed
What changed in the outcomes
  • RemovedPreliminary clinical activity as evaluated per European LeukemiaNet (ELN) 2022 criteria for AML and International Working Group (IWG) 2023 criteria for HR-MDSTime frame: 12 months
Oct 20, 2026
Secondary outcomes
4 edited, 1 added
What changed in the outcomes
  • EditedArea under the plasma concentration time curve extrapolated to the last measurable time point [AUClast] of eganelisib, cytarabine, and cytarabineazacitidineTime frame: 112 days
  • EditedMaximum concentration [Cmax] of eganelisib, cytarabine, and cytarabineazacitidineTime frame: 112 days
  • EditedTime of maximum concentration [Tmax] of eganelisib, cytarabine, and cytarabineazacitidineTime frame: 112 days
  • EditedPlasma half-life [t1/2] of eganelisib, cytarabine, and cytarabineazacitidineTime frame: 112 days
  • AddedPreliminary clinical activity as evaluated per European LeukemiaNet (ELN) 2022 criteria for AML and International Working Group (IWG) 2023 criteria for HR-MDS and FDA 2025 draft guidanceTime frame: 12 months
Oct 20, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Moffitt Cancer Center · Tampa, United StatesContact W•••@moffitt.org · •••0851→M•••@moffitt.org · •••0851
  • Washington University in St Louis · St Louis, United StatesContact n•••@wustl.edu · •••8708→a•••@wustl.edu · •••8708
Oct 20, 2026
Title
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    1 site removed. Memorial Sloan Kettering Cancer Center is now Recruiting
    Show 1 removed
    • Memorial Sloan Kettering Cancer Center · New York, United States
    Primary completion Jul 15, 2027→Dec 15, 2027
    Study completion Mar 15, 2028→Sep 15, 2028
    Enrollment 125→105
    Eligibility 1 inclusion criterion edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • EditedPart 1: Pathological diagnosis of either: AML according to World Health Organization (WHO) 2022 revised criteria per the local pathology report and with ≥10% bone marrow blasts (acute promyelocytic leukemia is excluded but secondary AML and treatment-related AML can be included); Higher-risk (IPSS-R Intermediate, High or Very High Risk at time of study entry) myelodysplastic syndromes (HR-MDS) according to WHO 2022 revised criteria per the local pathology report and with ≥10% bone marrow blasts.
    • AddedPart 2: Pathological diagnosis of previously untreated HR-MDS according to WHO 2022 revised criteria, with bone marrow blasts ≥5% and <20%; Moderate or higher PI3K-Gamma in bone marrow blasts, as determined by an IHC assay; Deemed by the Investigator to require frontline therapy with azacitidine.
    Primary outcomes 1 removed
    What changed in the outcomes
    • RemovedPreliminary clinical activity as evaluated per European LeukemiaNet (ELN) 2022 criteria for AML and International Working Group (IWG) 2023 criteria for HR-MDSTime frame: 12 months
    Secondary outcomes 4 edited, 1 added
    What changed in the outcomes
    • EditedArea under the plasma concentration time curve extrapolated to the last measurable time point [AUClast] of eganelisib, cytarabine, and cytarabineazacitidineTime frame: 112 days
    • EditedMaximum concentration [Cmax] of eganelisib, cytarabine, and cytarabineazacitidineTime frame: 112 days
    • EditedTime of maximum concentration [Tmax] of eganelisib, cytarabine, and cytarabineazacitidineTime frame: 112 days
    • EditedPlasma half-life [t1/2] of eganelisib, cytarabine, and cytarabineazacitidineTime frame: 112 days
    • AddedPreliminary clinical activity as evaluated per European LeukemiaNet (ELN) 2022 criteria for AML and International Working Group (IWG) 2023 criteria for HR-MDS and FDA 2025 draft guidanceTime frame: 12 months
    Interventions Added Drug: Eganelisib in combination with azacitidine·Drug: Azacitadine (AZA). Arms added: Eganelisib in combination with azacitidine·Azacitidine
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Moffitt Cancer Center · Tampa, United StatesContact W•••@moffitt.org · •••0851→M•••@moffitt.org · •••0851
    • Washington University in St Louis · St Louis, United StatesContact n•••@wustl.edu · •••8708→a•••@wustl.edu · •••8708
    Title Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS
    + 3 other changes: index terms, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06533761
Lead sponsor
Stelexis BioSciences
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Apr 28, 2025
Primary completion
Dec 15, 2027 (estimated)
Completion
Sep 15, 2028 (estimated)
Last update
Oct 20, 2026

Study contacts

Clinical Trials Office Stelexis
Contact
clinicaltrials@stelexis.com
508-543-6979

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: IPI-549 · Cytarabine · Azacitidine

Start the discussion